Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.

107 patients were identified with the following metastatic breast cancer subtypes: hormone receptor-positive (HR+), HER2-negative (HER2-) (n = 26, 24.3%), HER2+ (n = 45, 42.1%), and triple-negative (TNBC; n = 36, 33.6%).

At time of initial brain metastasis surgical resection, 55 patients (51.4%) had CNS-only disease and 63 patients (58.9%) had a single brain metastasis.

Most patients received systemic therapy after brain metastasis resection (n = 83/95 with available systemic therapy records, 87.4%) and postoperative radiation (n = 92/103 with available post-operative radiation records, 89.3%).